As­traZeneca auc­tions off rights to an­oth­er pipeline drug as Take­da grabs $400M Parkin­son's deal

As­traZeneca has sold off mar­ket­ing and de­vel­op­ment rights to an­oth­er one of its pipeline as­sets.

This time it’s Take­da that’s step­ping up, ink­ing a deal pack­age to­tal­ing $400 mil­lion for de­vel­op­ment and com­mer­cial­iza­tion rights to its home grown ME­DI1341, an al­pha-synu­cle­in an­ti­body de­signed to com­bat Parkin­son’s dis­ease.

As­traZeneca’s re­search team will hand the drug over to Take­da at the end of a Phase I study. Then the strug­gling phar­ma gi­ant will share in the cost of de­vel­op­ment and com­mer­cial­iza­tion — if it comes to that — while al­so shar­ing any prof­its.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER